Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 12, 2025

Study Completion Date

May 1, 2026

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

mFOLFIRINOX

mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.

DRUG

Gemcitabine / Nab-paclitaxel

Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.

Trial Locations (1)

L8V1C3

RECRUITING

Juravinski Hospital, Hamilton

All Listed Sponsors
lead

Hamilton Health Sciences Corporation

OTHER